Colorectal Cancer | Specialty

The OncLive Colorectal Cancer condition center page is a comprehensive resource for clinical news and expert insights on colorectal cancer treatment and management, with a focus on novel therapeutic strategies including checkpoint inhibitors and TKIs across lines of therapy. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in colorectal cancer.

OncLive’s FDA Approval Report: The Regulatory Rundown for April 2025

May 1st 2025

Here is your snapshot for all therapeutic options that were cleared by the FDA in April 2025 spanning tumor types.

Adjuvant Trifluridine/Tipiracil Benefit is Limited to Select Subgroups in MRD+ CRC

April 30th 2025

Trifluridine/tipiracil showed a favorable safety profile and numerically improved DFS vs placebo in MRD-positive CRC.

The Evolution of ctDNA Assays in CRC

April 30th 2025

Scott Kopetz, MD, PhD, FACP, and Mark A. Lewis, MD, discuss how ctDNA assays have improved MRD detection in CRC.

How ctDNA Is Informing Ongoing Trials in CRC

April 30th 2025

Scott Kopetz, MD, PhD, FACP, and Mark A. Lewis, MD, discuss ongoing research in CRC utilizing ctDNA.

Talking to Patients With CRC About ctDNA

April 30th 2025

Scott Kopetz, MD, PhD, FACP, and Mark A. Lewis, MD, discuss how to approach conversations about ctDNA with patients with CRC.

Implications From the BESPOKE CRC Study Evaluating ctDNA in Stage II-III CRC

April 30th 2025

Scott Kopetz, MD, PhD, FACP, and Mark A. Lewis, MD, discuss findings for ctDNA in stage II/III CRC from the BESPOKE CRC trial.

CIRCULATE-Japan: Diving Into ctDNA and DFS Data in Stage II-IV CRC

April 30th 2025

Scott Kopetz, MD, PhD, FACP, and Mark A. Lewis, MD, on data from the GALAXY arm of CIRCULATE-Japan for ctDNA in stage II to IV CRC.

Why ctDNA Remains a Focal Point in CRC Research

April 30th 2025

Scott Kopetz, MD, PhD, FACP, and Mark A. Lewis, MD, on why ctDNA remains a focus of research in colorectal cancer.

Sequencing Regorafenib After Fruquintinib Improves OS in mCRC

April 29th 2025

Initial fruquintinib followed by regorafenib extended OS vs the reverse sequence of the agents in patients with metastatic colorectal cancer.

Dr Cecchini on the Efficacy of Neoadjuvant Chemotherapy in CRC Liver Metastases

April 29th 2025

Michael Cecchini, MD, discusses the effects of neoadjuvant chemotherapy on tumor-infiltrating lymphocyte levels in colorectal cancer with liver metastases.

Maintenance Fruquintinib Plus Capecitabine Is Active, Tolerable in RAS/BRAF Wild-Type mCRC

April 29th 2025

Fruquintinib plus capecitabine demonstrated preliminary efficacy and safety as maintenance therapy in RAS/BRAF wild-type metastatic colorectal cancer.

Neoadjuvant Dostarlimab Eradicates Disease in 82% of Mismatch Repair–Deficient Solid Tumors

April 29th 2025

Eighty percent of patients with early-stage dMMR solid tumors given neoadjuvant dostarlimab underwent nonoperative management of their disease.

Dr Haldar on Outcomes for NeoAg-VAX With or Without Pembrolizumab in MSS mCRC

April 28th 2025

S. Daniel Haldar, MD, discusses outcomes for NeoAg-Vax with or without pembrolizumab in MSS metastatic colorectal cancer.

Encorafenib/Cetuximab Plus mFOLFOX6 Provides New SOC for BRAF V600E+ mCRC

April 16th 2025

Scott Kopetz, MD, PhD, FACP, highlights the efficacy of encorafenib/cetuximab with mFOLFOX6 in BRAF V600E–mutated metastatic colorectal cancer.

Five Under 5: Top Oncology Videos for the Week of 4/6

April 13th 2025

The top 5 OncLive videos of the week cover insights in myelofibrosis, chronic lymphocytic leukemia, colorectal cancer, breast cancer, and ovarian cancer.

The OncFive: Top Oncology Articles for the Week of 4/6

April 12th 2025

Nivolumab/ipilimumab is approved for dMMR/MSI-H mCRC and unresectable or metastatic HCC, larotrectinib wins full approval in NTRK+ solid tumors, and more.

FDA Greenlights Bevacizumab Biosimilar in Multiple Solid Tumor Indications

April 10th 2025

The bevacizumab biosimilar Jobevne was approved by the FDA for the treatment of several solid tumor types, including mCRC, NSCLC, and RCC.

Dr Bando on Safety of TAS-102 in MRD+ Resected CRC

April 9th 2025

Hideaki Bando, MD, PhD, discusses the safety of trifluridine/tipiracil in patients with MRD following resection of CRC.

FDA Approves Nivolumab Plus Ipilimumab for dMMR/MSI-H Metastatic CRC

April 8th 2025

The FDA has granted approval to nivolumab plus ipilimumab for the treatment of patients with dMMR/MSI-H metastatic colorectal cancer.

ctDNA-Guided Approaches Reveal Effective Adjuvant Agents in MRD+ CRC

April 7th 2025

Tanios S. Bekaii-Saab, MD, details studies of ctDNA-guided strategies that are elucidating the role of adjuvant therapies in CRC and agents of promise.